Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Personnel, Trade Show, Webcast

Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference


Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of its Executive Management Team will participate in a fireside chat at the Goldman Sachs 40th Annual Healthcare Conference on Wednesday, June 12, 2019 at 9:20 a.m. P.D.T. in Rancho Palos Verdes, California.

A live webcast of the fireside chat will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. A replay will also be available following the webcast.

About Aimmune

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for life-threatening food allergies. The company's Characterized Oral Desensitization ImmunoTherapy (CODITtm) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune's first, investigational, complex biologic product, AR101, is being developed as a treatment to reduce the frequency and severity and adverse events following exposure to peanut. The BLA for AR101 is under review by the FDA, which granted AR101 Breakthrough Therapy Designation in 2015 for the desensitization of peanut-allergic patients 4 to 17 years of age. The Allergenic Products Advisory Committee (APAC) of the FDA will review the BLA for AR101 at a meeting scheduled for September 13, 2019. Aimmune has filed an IND application for its second product, AR201 for the treatment of egg allergy, and intends to start a randomized phase 2 clinical trial in mid-2019. For more information, please see www.aimmune.com.


These press releases may also interest you

at 15:10
Ventech Solutions, Inc. is proud to have achieved several industry-leading certifications including CMMI® Institute's Capability Maturity Model® Integration (CMMI) Maturity Level 3 for Development and Services, as well as an Integrated Management...

at 15:00
ProMIS Neurosciences, Inc. , a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, presented data today for its lead clinical...

at 15:00
Dr. Charles Safran, an internationally renowned expert in applied healthcare informatics, has been named Chairman of the Clinical Advisory Board of HydraCor, LLC. He will be advising the New Hampshire-based company on the development of new clinical...

at 15:00
Avante Health Solutions is pleased to welcome Craig Rothman as the company's Director of Health Systems. Rothman joins the Avante team with more than 25 years of healthcare products and services experience, with the last 16 years spent specifically...

at 14:37
The Massachusetts Nurses Association Board of Directors ? 29 front-line nurses and health care professionals elected by their colleagues ? has issued the following statement about the current Administration's immigration policies and their effect on...

at 14:35
Ascent Industries Corp. ("Ascent") announces Annabeth Rose is joining the new Management Team to lead operations at the Portland, Oregon facility. Annabeth brings 15 years of laboratory experience with expertise in building and leading teams, and...



News published on 5 june 2019 at 08:05 and distributed by: